Shares of CSL (ASX:CSL) fell 1% in recent Tuesday trade after the company said in a late Monday statement that its unit, CSL Behring Canada, signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Hemgenix, the unit's gene therapy to treat adults with the life-threatening rare disease Hemophilia B.

Under the LOI, provinces and territories outside of Quebec will list Hemgenix as part of their formularies, the statement said.

CSL Behring is in talks with the province of Quebec to secure public reimbursement for Hemgenix, the statement added.